This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

lenalidomide (Revlimid®)

Reference No. 4171

Publication date:

Appraisal information

lenalidomide (Revlimid®) 2.5 mg capsule
lenalidomide (Revlimid®) 5 mg capsule
lenalidomide (Revlimid®) 7.5 mg capsule
lenalidomide (Revlimid®) 10 mg capsule
lenalidomide (Revlimid®) 15 mg capsule
lenalidomide (Revlimid®) 20 mg capsule
lenalidomide (Revlimid®) 25 mg capsule

Company: Celgene Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 16/09/2019

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, lenalidomide (Revlimid®) cannot be endorsed for use within NHS Wales as combination therapy with bortezomib and dexamethasone, or melphalan and prednisone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.
Statement of Advice (SOA)